Catalog_No | Drug Name/ Product Name |
CAS | Product Line | Target | Path | Area | Citation |
HY-78921 | Fmoc-3VVD-OH | 863971-44-2 | ADC Related | ADC Linker | Antibody-drug Conjugate/ADC Related | Cancer | [A1] |
HY-78931 | Boc-Dap-NE | 160800-65-7 | ADC Related | ADC Linker | Antibody-drug Conjugate/ADC Related | Cancer | |
HY-13631E | Deruxtecan | 1599440-13-7 | ADC Related | Drug-Linker Conjugates for ADC | Antibody-drug Conjugate/ADC Related | Cancer | [C1] [C2] |
HY-78738 | MC-Val-Cit-PAB | 159857-80-4 | ADC Related | ADC Linker | Antibody-drug Conjugate/ADC Related | Cancer | [D1] |
HY-15575 | VcMMAE | 646502-53-6 | ADC Related | Drug-Linker Conjugates for ADC; Microtubule/Tubulin | Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage; Cytoskeleton | Cancer | [E1]
[E2] [E3] |
HY-15162 | Monomethyl auristatin E | 474645-27-7 | ADC Related | ADC Cytotoxin; Apoptosis; Microtubule/Tubulin | Antibody-drug Conjugate/ADC Related; Apoptosis; Cell Cycle/DNA Damage; Cytoskeleton | Cancer | [F1]
[F2] |
HY-128952 | Tesirine | 1595275-62-9 | ADC Related | DNA Alkylator/Crosslinker; Drug-Linker Conjugates for ADC | Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage | Cancer | [G1]
[G2] |
HY-13631D | Dxd | 1599440-33-1 | ADC Related | ADC Cytotoxin; Topoisomerase | Antibody-drug Conjugate/ADC Related; Cell Cycle/DNA Damage | Cancer | [H1] |
HY-138298 | Trastuzumab deruxtecan (solution) | 1826843-81-5 | ADC Related | Antibody-Drug Conjugates (ADCs); EGFR | Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK | Cancer | [I1]
[I2] [I3] [I4] |
HY-138298A | Trastuzumab deruxtecan | 1826843-81-5 | ADC Related | Antibody-Drug Conjugates (ADCs); EGFR | Antibody-drug Conjugate/ADC Related; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK | Cancer | [J1]
[J2] [J3] [J4] |
[A1]. Michinori Akaiwa, et al. Synthesis and Evaluation of Linear and Macrocyclic Dolastatin 10 Analogues Containing Pyrrolidine Ring Modifications. ACS Omega. 2018 May 31;3(5):5212-5221.
[C1]. NOGUCHI, Shigeru, et al. METHOD FOR SELECTIVELY MANUFACTURING ANTIBODY-DRUG CONJUGATE. WO2017002776A1.
[C2]. Ogitani Y, et al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.
[D1]. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders.
[E1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.
[E2]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87.
[E3]. Jianmin Fang, et al. Anti-her2 antibody and conjugate thereof. US 20160304621 A1.
[F1]. Okeley, et al. Intracellular Activation of SGN-35, a Potent Anti-CD30 Antibody-Drug Conjugate. Clinical Cancer Research (2010), 16(3), 888-897.
[F2]. Lisa Buckel, et al. Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery. Cancer Res. 2015 Apr 1;75(7):1376-87.
[G1]. Tiberghien AC, et al. Design and Synthesis of Tesirine, a Clinical Antibody-Drug Conjugate Pyrrolobenzodiazepine Dimer Payload. ACS Med Chem Lett. 2016;7(11):983-987. Published 2016 May 24.
[G2]. Hartley JA, et al. Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine. Sci Rep. 2018;8(1):10479. Published 2018 Jul 11.
[H1]. Ogitani Y, et al. DS-8201a, A Novel HER2-Targeting ADC with a Novel DNA Topoisomerase I Inhibitor, Demonstrates a Promising Antitumor Efficacy with Differentiation from T-DM1. Clin Cancer Res. 2016 Oct 15;22(20):5097-5108.
[I1]. Kumagai K, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020 Dec;111(12):4636-4645.
[I2]. Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518.
[I3]. Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.
[I4]. Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280.
[J1]. Kumagai K, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020 Dec;111(12):4636-4645.
[J2]. Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518.
[J3]. Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46.
[J4]. Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280.
![]() |
Life Technologies (India) Pvt Ltd. 306, Agarwal City Mall, opposite M2K Pitampura, Delhi-110034 (India) Tel # +91-11-4220-8000; 4220-8111; 4220-8222 Fax# +91-11-4220-8444, Mobile# +91-98105-21400, Toll Free# 1800-120-2434 Email# customerservice@lifetechindia.com |